The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Notice of annual general meeting in Intervacc AB (publ)
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Wednesday 9 June 2021. Due to the continued spread of the coronavirus and the authorities’ regulations/advice on...Intervacc AB and Dechra Pharmaceuticals PLC enter into an Agreement to Commercialize Strangvac in Europe
Stockholm, April 12, 2021 – Intervacc AB (“Intervacc”) announced today that they have entered into an exclusive distribution agreement with Dechra Pharmaceuticals PLC, (“Dechra”) to commercialize Intervacc’s leading vaccine candidate Strangvac® in Europe,...Intervacc publishes the 2020 Annual Report
Stockholm, March 31, 2021 – Intervacc AB (publ) announces that the company’s 2020 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on the...DNA investigation highlights the ‘unbridled globetrotting’ of the Strangles pathogen in horses
Stockholm, March 9, 2021 – In the largest ever study of its kind into an equine pathogen, which was published today in the journal ‘Microbial Genomics’, scientists in 18 countries used the latest DNA sequencing techniques to track the bacteria...Nyhetstjänster
